| Literature DB >> 33521534 |
David Kerr1, Souptik Barua2, Namino Glantz1, Casey Conneely1, Mary Kujan1, Wendy Bevier1, Arianna Larez1, Ashutosh Sabharwal2.
Abstract
INTRODUCTION: Poor diet is the leading cause of poor health in USA, with fresh vegetable consumption below recommended levels. We aimed to assess the impact of medical prescriptions for fresh (defined as picked within 72 hours) vegetables, at no cost to participants on cardiometabolic outcomes among adults (predominantly Mexican-American women) with or at risk of type 2 diabetes (T2D).Entities:
Keywords: diabetes mellitus; dietary patterns; metabolic syndrome; nutritional treatment
Year: 2020 PMID: 33521534 PMCID: PMC7841821 DOI: 10.1136/bmjnph-2020-000133
Source DB: PubMed Journal: BMJ Nutr Prev Health ISSN: 2516-5542
Figure 1Participation flow between February 2019 and March 2020. Note: Recruitment and follow-up visits were cancelled after March 2020 due to the COVID-19 pandemic. CGM, continuous glucose monitors.
Baseline characteristics of all enrolled participants
| Total | ||
|
| 159 (122 female) | |
|
| 52.5+13.2 | |
| Female | 52.3+12.4 | |
| Male | 53.3+15.4 | |
|
|
| |
|
| ||
| Hispanic/Latino | 119 | 75% |
| Non-Hispanic white | 32 | 20% |
| African-American | 4 | 2.5% |
| Asian | 3 | 2% |
| Native American | 1 | 0.5% |
|
| ||
| Mexico | 100 | 63% |
| Central/South America | 7 | 4% |
| USA | 45 | 28% |
| Other | 6 | 4% |
| No data | 1 | 0.6% |
|
| ||
| Employed | 139 | 86% |
| Unemployed | 9 | 6% |
| Retired | 11 | 8% |
|
| ||
| Has insurance | 103 | 65% |
| No insurance | 56 | 35% |
|
| ||
| Has diabetes | 49 | 31% |
| At risk for diabetes (HbA1c <5.7%) | 40 | 25% |
| Prediabetes (HbA1c 5.7% to 6.4%) | 70 | 44% |
T2D, type 2 diabetes.
Comparison of baseline data for participants providing baseline and postintervention (n=131) versus participants providing data on their first visit only (n=28). Results shown as mean±SD
| Variable | Participants with paired data | Participants with baseline data only | P value |
| Weight (kg) | 80.4±19.5 | 88.2±26.3 | 0.073 |
| Waist circumference (cm) | 102.7±14.1 | 102.6±14.5 | 0.977 |
| Systolic blood pressure (mm Hg) | 121.3±15.2 | 115.0±16.9 | 0.054 |
| Diastolic blood pressure (mm Hg) | 67.8±9.3 | 71.2±8.8 | 0.078 |
| HbA1c (%) (median (IQR)) | 6.0 (5.7 to 6.6) | 6.3 (5.4 to 8.0) | 0.897 |
| Sleep (mm)* | 56 (43 to 75) | 50 (44 to 75) | 0.667 |
| Mood (mm)* | 70 (50 to 82) | 60 (49 to 82) | 0.441 |
| Pain (mm)* | 61 (35 to 85) | 60 (59 to 96) | 0.441 |
*Self-reported sleep, mood and pain scores using 100 mm Visual Analogue Scales with a range from 0 (worst sleep/worst mood/worst pain) to 100 (for best sleep/best mood/no pain).
Comparison of variables collected at first and final visits for participants with paired data (ie, at baseline and from the final visit). Results are shown as mean±SD unless otherwise stated
| Variable | Subgroup | Number | Baseline | Final | P value |
|
|
|
|
|
| |
| Female | 107 | 79.4±18.6 | 78.7±18.6 | 0.03 | |
| Male | 24 | 86.3±21.2 | 86.4±21.0 | NS | |
|
|
|
|
|
| |
| Female | 107 | 102.7±13.9 | 101.8±13.9 | 0.02 | |
| Male | 24 | 102.6±15.2 | 102.3±15.4 | NS | |
|
| Female >88 cm | 92 | 105.9±12.0 | 104.8±12.4 | 0.01 |
|
| Male >102 cm | 10 | 117.4±11.9 | 117.0±12.4 | NS |
|
|
|
|
|
| |
| Female | 107 | 121.9±15.9 | 119.2±16.7 | 0.04 | |
| Male | 24 | 118.7±11.3 | 117.2±12.1 | NS | |
|
| >130 mm Hg | 40 | 139.5±7.1 | 132.0±16.7 | 0.005 |
|
| 6.0 (5.7 to 6.6) | 6.1 (5.7 to 6.6) | NS | ||
|
| <5.7% | 29 | 5.6 (5.5 to 5.6) | 5.6 (5.4 to 5.7) | NS |
| 5.7%–6.4% | 63 | 5.9 (5.8 to 6.1) | 6.0 (5.8 to 6.2) | NS | |
|
| 39 | 7.4 (6.7 to 8.0) | 7.2 (6.6 to 7.7) | 0.02 | |
|
| 25 | 7.9 (7.4 to 8.5) | 7.6 (7.1 to 8.1) | 0.009 | |
|
| 131 | 56 (43 to 75) | 73 (50 to 80) | <0.0001 | |
|
| 131 | 70 (50 to 82) | 75 (58 to 88) | 0.004 | |
|
| 131 | 61 (35 to 85) | 73 (49 to 99) | 0.007 |
*Self-reported sleep, mood and pain scores using 100 mm Visual Analogue Scales with a range from 0 (worst sleep/worst mood/worst pain) to 100 (for best sleep/best mood/no pain).
NS, not significant.
Figure 2Change in average glucose, glucose variability measured as the percentage coefficient of variation (%CV) and time in range (TIR) (70–180 mg/dL) for n=40 participants wearing CGM at baseline and at 3 months. Participants are stratified by baseline HbA1c at baseline into at-risk (HbA1c < 5.7%), pre-T2D (HbA1c 5.7%–6.4%), and T2D (HbA1c > 6.4%). A positive value represents an increase of the CGM variable from baseline to 3 months, while a negative value represents a corresponding decrease. Results are shown as box plots (*p<0.05, **p<0.01). CGM, continuous glucose monitor; T2D, type 2 diabetes.
Variables collected on participants returning for a visit 3 months after completing the Farming for Life programme. Results are shown as mean+SD unless otherwise stated
| Variable | Baseline visit n=47 | Final visit n=47 | 6-month visit n=47 |
| Waist circumference (cm) | 102.1±15.5 | 100.8±13.9 | 100.8±13.7 |
| Systolic blood pressure | 121.2±13.1 | 119.5±18.7 | 117.1±13.3* |
| HbA1c (%) median (IQR) | 6.1 (5.7 to 6.8) | 6.0 (5.7 to 6.7) | 5.9 (5.6 to 6.7)* |
*p=0.03.